tetano
Editor, Senior Moderator
Front Public Health
. 2026 Jan 22:14:1738942.
doi: 10.3389/fpubh.2026.1738942. eCollection 2026.
Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data
Sijia Liu[SUP] 1 [/SUP], Tiange Zhou[SUP] 1 [/SUP], Mengmeng Wang[SUP] 1 [/SUP], Wanwan Xiang[SUP] 1 [/SUP], Jiancai Wu[SUP] 1 [/SUP]
Affiliations
mRNA vaccines, as a novel vaccine platform, have rapidly become a global research hotspot driven by the COVID-19 pandemic. This study employs a systematic analysis method based on clinical trial registries to conduct a descriptive statistical analysis of mRNA vaccine-related trials registered in the ClinicalTrials.gov database from March 2000 to July 2025. We compared characteristics such as the number of trials, geographical distribution, study type, funding sources, trial design, and indications, and used chi-square tests and Fisher's exact tests for inter-group difference analysis. The results show that the number of mRNA vaccine clinical trials has experienced explosive growth after the pandemic, presenting obvious pandemic-driven characteristics and geographical differences. There are significant differences in registration characteristics and trial design among China, the United States, and Europe (p<0.01). Indications have rapidly expanded from infectious diseases to multiple fields such as tumors, autoimmune diseases, and metabolic diseases, indicating that mRNA technology is transforming from an infectious disease prevention tool into a platform technology with broad therapeutic potential. From the perspective of clinical trial registration, this study provides empirical evidence for understanding the global research status, regional strategy differences, and future development directions of mRNA vaccines. It offers insights for vaccine development planning, international regulatory coordination, and global clinical trial strategic planning, assisting researchers, enterprises, and policymakers in making optimal decisions.
Keywords: COVID-19; clinical trials; mRNA; mRNA vaccines; vaccines.
. 2026 Jan 22:14:1738942.
doi: 10.3389/fpubh.2026.1738942. eCollection 2026.
Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data
Sijia Liu[SUP] 1 [/SUP], Tiange Zhou[SUP] 1 [/SUP], Mengmeng Wang[SUP] 1 [/SUP], Wanwan Xiang[SUP] 1 [/SUP], Jiancai Wu[SUP] 1 [/SUP]
Affiliations
- PMID: 41657702
- PMCID: PMC12872791
- DOI: 10.3389/fpubh.2026.1738942
mRNA vaccines, as a novel vaccine platform, have rapidly become a global research hotspot driven by the COVID-19 pandemic. This study employs a systematic analysis method based on clinical trial registries to conduct a descriptive statistical analysis of mRNA vaccine-related trials registered in the ClinicalTrials.gov database from March 2000 to July 2025. We compared characteristics such as the number of trials, geographical distribution, study type, funding sources, trial design, and indications, and used chi-square tests and Fisher's exact tests for inter-group difference analysis. The results show that the number of mRNA vaccine clinical trials has experienced explosive growth after the pandemic, presenting obvious pandemic-driven characteristics and geographical differences. There are significant differences in registration characteristics and trial design among China, the United States, and Europe (p<0.01). Indications have rapidly expanded from infectious diseases to multiple fields such as tumors, autoimmune diseases, and metabolic diseases, indicating that mRNA technology is transforming from an infectious disease prevention tool into a platform technology with broad therapeutic potential. From the perspective of clinical trial registration, this study provides empirical evidence for understanding the global research status, regional strategy differences, and future development directions of mRNA vaccines. It offers insights for vaccine development planning, international regulatory coordination, and global clinical trial strategic planning, assisting researchers, enterprises, and policymakers in making optimal decisions.
Keywords: COVID-19; clinical trials; mRNA; mRNA vaccines; vaccines.